Among patients who undergo the 21-gene assay (21-GA), 39% to 67% receive an intermediate risk result and may receive ambiguous treatment guidance. The 70-gene signature assay (70-GS) may be associated with physicians' treatment decisions in this population with early breast cancer.
T he 70-gene signature assay (70-GS) is a US Food and Drug Administration-cleared molecular diagnostic assay that provides a binary classification for patients with earlystage breast cancer into low or high risk for breast cancer recurrence. The 70-GS was developed by identifying the genes most correlated with disease outcome in systemically untreated patients. The signature probes were selected in a datadriven and unbiased fashion from approximately 25 000 genes representing the entire human genome. 1 The 70-GS was evaluated in a randomized, prospective, phase 3 clinical trial that validated the clinical utility of the assay in patients with early breast cancer, regardless of estrogen receptor (ER) or human epidermal growth factor receptor 2 (HER2) status. The Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) trial provided evidence that patients with a 70-GS low risk could safely forego chemotherapy (CT) without detrimentally affecting outcome. 2 The 70-GS identified 46% of clinically high-risk patients as genomically low risk, with 5-year distant metastasis-free survival of 94.7%, similar to 95.0% among patients classified as clinically low risk. Among patients with ER-positive, lymph node (LN)-negative, HER2-negative disease who were at clinically and 70-GS low risk, 98.4% had a distant metastasis-free interval at 5 years without CT. The 21-gene assay (21-GA) was developed by selecting 16 genes associated with recurrence-free survival in patients with ER-positive, HER2-negative findings who received 5 years of tamoxifen therapy. These cancer-related genes (ER, PR, BCL2, SCUBE2, Ki67, STK15, Survivin, cyclin B1, MYBL2, MMP11, CTSL2, GFB7, HER2, GSTM1, CD68, and BAG1) and 5 reference genes were chosen from a panel of 250 candidate genes curated from published literature and genomic databases. The retrospective analysis of tamoxifen-treated patients from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 trial was used to validate the 21-GA. The trial showed significantly better 10-year distant recurrence-free survival among patients classified as low risk by the 21-GA (recurrence score [RS] , <18) compared with patients classified as high risk (RS, >30), but the results for the group with intermediate risk (RS, (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) were inconclusive. 3 Similar to the MINDACT trial, the Trial Assigning Individualized Options for Treatment (TAILORx) plans to report results validating the clinical utility of the 21-GA in patients with ER-positive, HER2-negative, LN-negative breast cancer. 4 However, unlike the MINDACT trial, the low-and high-risk patients are not being randomized to receive CT. All patients with an RS less than 11 (TAILORx low risk) are forgoing CT, and all patients with an RS of at least 26 (TAILORx high risk) are receiving CT. 
Methods

Study Population
The PROMIS trial enrolled 876 patients with breast cancer and an intermediate 21-GA result from May 20, 2012, through December 31, 2015. Eighteen patients did not pass the 70-GS quality check. An additional 18 patients were removed from this analysis for the following reasons: 4 were ineligible for unknown reasons, 1 did not complete the informed consent form, 2 withdrew for unknown reasons, 3 started treatment before receiving the test result, 3 had a history of cancer treatment, 3 were duplicated in the enrolled population, and 2 had unresolved case report form queries. The 840 eligible patients had LN-negative or LN-positive (N1) disease, were negative for HER2, and were positive for hormone receptor. Enrollment was contingent on receiving a successful 70-GS (ie, MammaPrint) result. The industry-sponsored trial was approved by institutional review boards in all 58 participating US institutions and registered with clinicaltrials.gov (NCT01617954). 6 Before enrollment, patients were required to provide written informed consent to participate and for research use of their tumor samples. Originally, the trial was only open to patients with LNnegative disease; the protocol was amended in March 2013 to allow for the inclusion of patients with LN-positive disease. By this time, the validity of the 70-GS and 21-GA in patients with as many as 3 positive nodes had been validated in multiple studies. 7, 8 The inclusion of patients with LN-positive disease in the PROMIS trial also coordinated with the concurrently running MINDACT (70-GS) and Rx for Positive Node, Endocrine Responsive Breast Cancer (RxPONDER; 21-GA) trials, 9 both of which were enrolling patients with as many as 3 positive nodes.
Key Points
Question Are 70-gene signature assay findings associated with physicians' treatment decisions for patients with intermediate findings on the 21-gene assay?
Findings In this study of 840 patients with early breast cancer, 282 physicians (33.6%) changed their treatment decision after receiving the 70-gene assay result. Adjuvant chemotherapy was added and removed so that 88% of high-risk patients were recommended to receive chemotherapy and 91% of low-risk patients were recommended no chemotherapy.
Meaning The 70-gene signature assay provides clinically actionable information, and the findings may be associated with adjuvant therapy decisions.
Adjuvant therapy was at the discretion of the treating physician. Physicians provided their recommended adjuvant treatment plan before the 70-GS results were available. After receiving the 70-GS results, the same treating physician provided his or her recommended treatment plan again.
Molecular and Immunohistochemical Assessment
The 70-GS was performed at the centralized Agendia laboratory in Irvine, California, according to standard protocols described previously. 10 This test is based on microarray gene expression analysis of RNA extracted from formalin-fixed, paraffin-embedded breast tumor tissue and uses customdesigned array chips manufactured by Agilent Technologies. The 70-GS provides a numerical index ranging from −1.000 to 1.000 and a dichotomous categorization of low risk or high risk depending on whether the index is greater than 0 (low risk) or 0 or less (high risk). The 70-GS index is calculated from the correlation of a patient's tumor profile to known low-and highrisk tumor profiles. Therefore, the more extreme the 70-GS index value, the more similar the tumor is to the hallmark low-or high-risk profiles. The statuses of ER, progesterone receptor (PR), HER2, and Ki67 were determined by the local institution using pretreatment samples according to American Society of Clinical Oncology and College of American Pathologists testing guidelines.
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Statistical Analysis
Available data from previous studies were used to calculate the target sample size needed to investigate the hypothesis of a 20% overall treatment change with sufficient power after revealing 70-GS results to the investigator (820 participants for a significance level of .05 and power of 0.90). The overall treatment change was defined as the percentage of patients with a change from their baseline treatment recommendation after receiving the 70-GS result. of the trial population), an equal number of patients (218 each) were recommended to receive and to forego CT ( Figure 1 ). 
Association of the 70-GS With Adjuvant Therapy Recommendations
The 70-GS classifications were associated with significant changes in CT treatment decisions to add or withhold CT (Table 1) (χ 2 test, P < .001). The OR for removing CT was significantly higher for 70-GS low-risk patients who were initially recommended CT (OR, 108.00; 95% CI, 18.98-4304.77; McNemar P < .001) and was significantly lower for 70-GS highrisk patients who were initially recommended CT (OR, 0.01; 95% CI, 0.001-0.04; McNemar P < .001). Among all patients, the odds of patients recommended not to receive CT after receiving the 70-GS compared with patients initially recommended to receive CT before receiving the 70-GS test was 0.64 (95% CI, 0.50-0.82; McNemar P < .001). Overall, 282 adjuvant treatment recommendations (33.6%) changed after receipt of the 70-GS result; 108 of 374 patients (28.9%) with a low-risk 70-GS result had CT removed from their treatment recommendation, and 171 of 466 patients (36.7%) with a highrisk 70-GS result had CT added to their treatment recommendation. One patient with a low-risk 70-GS result had CT added, and 2 patients with high-risk 70-GS results had CT removed from their treatment recommendations. In this ER-positive population, 794 of 840 patients (94.5%) were recommended endocrine therapy (HT) before and 803 (95.6%) after the 70-GS ( Table 2) . Thirty-one patients had a change in HT recommendation. For 9 patients for whom CT was removed, HT was added to the treatment recommendation. Among 11 patients for whom CT was added, 7 had HT removed and 4 had HT added. Among 11 patients with no change in CT recommendation, 4 had HT removed and 7 had HT added. When analyzing the subgroup of 368 patients for whom the original physician-selected treatment recommendation (based on the intermediate 21-GA) conflicted with that indicated by the 70-GS, 279 (75.8%) of these patients had their treatment regimen changed; 108 of 142 70-GS low-risk patients who originally were recommended to receive CT had CT removed from their treatment recommendation, and 171 of 226 70-GS high-risk patients who originally were not recommended to receive CT had CT added to their treatment recommendation after the 70-GS result (Table 1) . Overall, results of the 70-GS were associated with physician adjuvant treatment recommendations; 339 of 374 low-risk patients (90.6%) were recommended no adjuvant CT, and 409 of 466 highrisk patients (87.8%) were recommended adjuvant CT. The change in treatment decision was the same regardless of LN status; 251 of 744 patients with LN-negative disease (33.7%) and 27 of 84 patients with LN-positive disease (32.1%) had a change to their CT treatment decision (eTable 2 in the Supplement). The decision to change treatment was significant in both groups (χ 2 test, P < .001 for LN-negative and P = .004 for LN-positive disease). Multivariable analysis showed that the 70-GS was the only independent variable significantly associated with the change in CT decision (hazard ratio, 1.85; 95% CI, 1.31-2.63) ( Table 3) . Nodal status, tumor stage, grade, histologic type, age, race, and menopausal or PR status were not associated with the change in CT decision. After receiving the 70-GS result, physicians were queried in every case as to how the result influenced their confidence level regarding the chosen treatment plan. Physicians reported greater confidence in their treatment recommendations in 660 cases (78.6%), reduced confidence in 49 cases (5.8%), and no effect on confidence in 131 cases (15.6%) after receiving the 70-GS result. Although all of the PROMIS study sites had previously used the 21-GA, one-third of the participating sites were not 70-GS users before the trial and twothirds were not regular or exclusive users of the 70-GS. 17 In the present trial, the initial decision to administer CT based on the 21-GA result was highly correlated with a high Ki67 expression of at least 14% (Yates χ 2 test, P = .01) (eTable 3 in the Supplement),
Discussion
indicating that physicians reverted to traditional clinicopathologic features to guide treatment decisions in patients with intermediate risk.
The PROMIS trial showed that physicians have greater confidence in their adjuvant treatment recommendation after re- ceiving results of the 70-GS when the 21-GA yielded an intermediate RS, indicating a limitation of the latter assay in guiding adjuvant treatment recommendations. The MINDACT trial showed that patients classified at low risk by the 70-GS index who belonged to a subset with ER-positive, HER2-negative, and LN-negative disease (744 [88.6%] of PROMIS patients) had a 5-year distant metastasis-free interval of 97.8% with no adjuvant CT. 2 This risk is sufficiently low to forgo adjuvant CT owing to the negligible absolute benefit in this population. Patients classified as low risk by the 70-GS from the Microarray Prognostics in Breast Cancer (RASTER) trial had a distant recurrence-free interval of 97.0% at 5 years (15% received CT). 18 In addition, in the prospective, randomized Stockholm Tamoxifen (STO-3) trial, 70-GS low-risk patients who received only 2 or 5 years of tamoxifen had a 10-year distant metastasis-free survival of 93% and a 20-year breast cancerspecific survival of 90%. 19, 20 Alternately, in 70-GS high-risk patients, adjuvant CT could be considered to optimize their disease-specific outcomes. In the MINDACT study, 70-GS highrisk patients from the same subgroup had a 94.6% distant metastasis-free interval at 5 years with adjuvant CT, whereas untreated 70-GS high-risk patients in the earlier prognostic validation studies had a probability of distant recurrence of 71%. 21, 22 Endocrine therapy alone was unlikely to account for the total risk reduction observed in this high-risk group.
Limitations
Recurrence and survival data were not collected as part of this study because the primary objective was to evaluate the change in treatment decision based on the information provided by the 70-GS. 
Conclusions
The purpose of a prognostic test is to provide physicians and patients with definitive and actionable information in combination with other factors for accurate risk assessment. The PROMIS trial observed that treatment recommendations based on the 70-GS or 21-GA were often discordant and that 75.8% of these patients changed their treatment regimen. Overall, the additional information from the 70-GS results was associated with a change in the physician's adjuvant therapy recommendation for 33.6% of all patients, and physicians followed the adjuvant therapy recommendation based on the 70-GS result for 748 patients (89.0%). The high proportion of cases in which physicians changed their treatment regimens by adding and removing CT, along with a self-reported increase in confidence, substantiates the influence of the 70-GS test when used for adjuvant decision making. Furthermore, obtaining additional molecular testing in cases with ambiguity may improve confidence in the adjuvant treatment plan. Accurately identifying patients who can safely forego CT prevents patients from undergoing a treatment that may minimally benefit them, sparing them from acute and long-term adverse effects, and would reduce the cost of health care for patients and payers. [23] [24] [25] Judicious use of genomic testing aids physicians in tailoring the episode of care to appropriate patient populations, both maximizing the value of and minimizing the risk for treatments. Although the recommendation to de-escalate therapy has proven to be one of the most difficult challenges in breast oncology, this study reveals that the 70-GS may provide physicians with clinically actionable information and improve their confidence in de-escalating therapy.
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